Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes Mellitus, Insulin-Dependent: early-phase trial registry
1 of 4 indexed Diabetes Mellitus, Insulin-Dependent trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Diabetes Mellitus, Insulin-Dependent: 4 US clinical trials tracked, 1 recruiting.
Diabetes Mellitus, Insulin-Dependent is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Insuline Medical, running 1 of these trials.
Enrollment posture brief
Registry condition diabetes-mellitus-insulin-dependent
OPEN 1 | RECR 25% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Diabetes Mellitus, Insulin-Dependent lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes Mellitus, Insulin-Dependent on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes Mellitus, Insulin-Dependent is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
University of Colorado, Denver
NCT07011147
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
Mesoblast
NCT00690066
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
Insuline Medical
NCT01216618
Islet Transplantation for Type 1 Diabetes
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00014911
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes Mellitus, Insulin-Dependent records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes Mellitus, Insulin-Dependent trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes Mellitus, Insulin-Dependent page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Diabetes Mellitus, Insulin-Dependent trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Insuline Medical sponsors the most Diabetes Mellitus, Insulin-Dependent trials on record, review their full trial history before evaluating a specific study. See Insuline Medical's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes Mellitus, Insulin-Dependent condition card totals 4 registered trials; most-linked intervention Sulfamethoxazole; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.